Published in Front Physiol on November 07, 2014
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol (2016) 0.80
Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies. Br J Clin Pharmacol (2015) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J (2012) 3.70
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther (2005) 2.63
A model for the stoichiometric regulation of blood coagulation. J Biol Chem (2002) 2.43
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost (2005) 2.16
Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res (2006) 1.78
A comprehensive model for the humoral coagulation network in humans. Clin Pharmacol Ther (2009) 1.56
Mathematical and biological models of blood coagulation. J Thromb Haemost (2005) 1.44
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem (2005) 1.40
Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med (1995) 1.34
Analysis of the activated partial thromboplastin time test using mathematical modeling. Thromb Res (2001) 1.25
Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med (2003) 1.06
Anticoagulation by factor Xa inhibitors. J Thromb Haemost (2010) 0.99
A mathematical model of lipid-mediated thrombin generation. Math Med Biol (2003) 0.98
Anticoagulants and the propagation phase of thrombin generation. PLoS One (2011) 0.89
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One (2011) 0.88
The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers. Eur J Clin Pharmacol (2001) 0.84
Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb (1994) 0.82
The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. Rev Cardiovasc Med (2004) 0.78
Evaluation of the blood coagulation mechanism and platelet aggregation in individuals with mechanical or biological heart prostheses. Blood Coagul Fibrinolysis (2002) 0.78
Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol (2002) 0.78